Literature DB >> 10892889

Mechanisms of aspirin chemoprevention of colorectal cancer.

H Vainio1, G Morgan.   

Abstract

Good evidence indicates that the regular consumption of aspirin reduces the risk of colorectal cancer by up to 50%. This paper discusses mechanisms for this protection and considers carcinogen activation, cell proliferation, apoptosis and immune surveillance. It is not clear, however, whether these mechanisms are dose related. This question will remain to be answered until the optimum dose and duration of aspirin required for protection against colorectal cancer is established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10892889     DOI: 10.1007/BF03190034

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  19 in total

Review 1.  Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents.

Authors:  L J Marnett; A S Kalgutkar
Journal:  Curr Opin Chem Biol       Date:  1998-08       Impact factor: 8.822

2.  Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines.

Authors:  D J Elder; A Hague; D J Hicks; C Paraskeva
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

3.  Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.

Authors:  T O Daniel; H Liu; J D Morrow; B C Crews; L J Marnett
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

4.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

Authors:  T C He; T A Chan; B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

5.  The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.

Authors:  N N Mahmoud; S K Boolbol; A J Dannenberg; J R Mestre; R T Bilinski; C Martucci; H L Newmark; A Chadburn; M M Bertagnolli
Journal:  Carcinogenesis       Date:  1998-01       Impact factor: 4.944

6.  Aspirin and aspirin-like drugs induce HLA-DR expression in HT29 colon cancer cells.

Authors:  P Arvind; L Qiao; E Papavassiliou; E Goldin; M Koutsos; B Rigas
Journal:  Int J Oncol       Date:  1996-06       Impact factor: 5.650

7.  Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines.

Authors:  P Arvind; E D Papavassiliou; G J Tsioulias; L Qiao; C I Lovelace; B Duceman; B Rigas
Journal:  Biochemistry       Date:  1995-04-25       Impact factor: 3.162

8.  The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development.

Authors:  B Rigas; G J Tsioulias; C Allan; R K Wali; T A Brasitus
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

9.  Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.

Authors:  D J Elder; D E Halton; A Hague; C Paraskeva
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

10.  Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts.

Authors:  X Zhang; S G Morham; R Langenbach; D A Young
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.